

Surrey Heartlands Locally Commissioned Services 2024

SHLCS-A16-2024-DM	Drug Administration and Monitoring
KEY ELEMENTS	<ul style="list-style-type: none"> ➤ A – Drug monitoring (Shared Care Drugs as listed) <ul style="list-style-type: none"> ➤ Continue under a Shared Care agreement as per PAD ➤ DMARDS (Methotrexate, Leflunomide, Penicillamine, Ciclosporin, Sulfasalazine, Azathioprine, Mercaptopurine, Hydroxychloroquine) ➤ Immunosuppressants (Mycophenolate – non-transplant only) ➤ Other (Riluzole for MND, Tolcapone or Apomorphine for PD, Amiodarone, Sodium Valproate for women of child-bearing age for Epilepsy or bipolar disorder only) ➤ B – Care Closer to Home <ul style="list-style-type: none"> ➤ Initiated in secondary care then prescribed & administered in primary care without full Shared Care agreement ➤ LHRH e.g. Zoladex and Degarelix – Not covered for the treatment for breast cancer ➤ C – Denosumab <ul style="list-style-type: none"> ➤ To be initiated, administered & monitored in Primary rather than Secondary Care ➤ D – Inclisiran <ul style="list-style-type: none"> ➤ Call/recall service and administration
OF SPECIAL NOTE	<ul style="list-style-type: none"> ➤ All patients need an individual treatment plan ➤ Make sure correct criteria for Denosumab and Inclisiran are met ➤ Any phlebotomy monitoring is covered by the phlebotomy LCS (separate claim)
RISKS	<ul style="list-style-type: none"> ➤ Must ensure PAD/treatment options have been followed appropriately ➤ You are agreeing to provide & take responsibility for monitoring ➤ Abnormal results are your responsibility to act on
PRACTICE CONSIDERATIONS	<ul style="list-style-type: none"> ➤ Up to date register needed for any injectables included (inc. Denosumab and Inclisiran) ➤ Up to date register for all Shared Care patients inc. defined info (see spec for details) ➤ “Robust” Call & Recall system must be in place for all patients ➤ Need a demonstrable system to manage patients not attending for administration and monitoring ➤ Protocols will be needed for different test profiles for different medications (as per PAD) ➤ Practices are recommended to use Ardens for data entry templates and SNOMED for codes.
PRICING	<ul style="list-style-type: none"> ➤ Drug Monitoring (per patient monitored and on register, per qtr.) - £23.85 ➤ Care Closer to Home (per appt.) - £14.71 ➤ Denosumab (per appt.) - £34.49 ➤ Inclisiran (per appt.) - £32.56